References Badenhorst, T., Svirskis, D., Wilsher, T., & O'Sullivan, J
An analysis of insurance claims for GLP-1 weight-loss therapy (in patients without diabetes) found only 29% were still on the medication at 1 year, and a mere 15% at 2 years (source)
Injection Site Reactions: Risk of infections, swelling, and pain at the injection site due to improper administration
As a small family business, we take great pride in delivering beautifully crafted, long-lasting street furniture that stands up to the harshest weather conditions and everyday wear and tear
No minimum effective dose or maximum tolerated dose has been established in human oral trials